On 4 July 2025, the EC fined Alchem and its subsidiary EUR 489,000 for their role in a long-running cartel concerning the active pharmaceutical ingredient SNBB, used in the production of Buscopan and its generics. This marks...more
7/23/2025
/ Antitrust Violations ,
Cartels ,
Competition ,
Drug Pricing ,
Enforcement Actions ,
EU ,
European Commission ,
Healthcare ,
Life Sciences ,
Penalties ,
Pharmaceutical Industry ,
Prescription Drugs
The European Commission (EC) has fined five pharmaceutical companies a total of EUR13.4 million for participating in a cartel concerning N-Butylbromide Scopolamine/Hyoscine (SNBB) – an active pharmaceutical ingredient (API)...more
10/23/2023
/ Cartels ,
Cephalon ,
Competition ,
Corporate Counsel ,
EU ,
European Commission ,
Generic Drugs ,
Life Sciences ,
Patents ,
Pay-For-Delay ,
Pharmaceutical Industry ,
Popular ,
Prescription Drugs ,
Teva Pharmaceuticals
In February 2022, the Belgian Competition Authority’s (the BCA) prosecution service (Auditoraat/Auditorat) adopted a settlement decision, sanctioning two pharmaceutical wholesalers, Pharma Belgium-Belmedis SA and Febelco CV,...more